Reactive oxygen species (ROS) are important in regulating normal cellular processes, but deregulated ROS contribute to the development of various human diseases including cancers.
antioxidant defenses and plays a central role in maintaining redox balance (NADP/NADPH and GSSG/GSH ratios), via its tight regulation of NADPH intracellular levels. The intracellular NADPH level is determined by the difference between its production and its consumption. The major sources of intracellular NADPH are the pentose phosphate pathway (PPP) and mitochondrial metabolism. The major consumers of intracellular NADPH are H 2 O 2 detoxification by GPX and PRX and fatty-acid synthesis (10) . Thus, the production and the consumption of NADPH inside cells should be coordinated in order to maintain NADPH homeostasis. This is particularly important during the formation of solid tumor and during metastasis when cancer cells undergo energetic stress.
ROS and Cancer
In the past two decades, cancer promotion and progression have been linked to oxidative stress by increasing DNA mutations or inducing DNA damage, genome instability, and cell proliferation (11−13) . Indeed, one of the main features of cancer cells, when compared to the normal ones, is a persistent pro-oxidative state that can lead to intrinsic oxidative stress (14, 15) .
The enhanced oxidative stress observed in cancer cells can result not only from ROS overproduction, but also from low levels or inactivation of antioxidant mechanisms. Survival of tumor cells is highly dependent on their capacity to control expression of endogenous antioxidants to maintain a steady state level of ROS below the threshold that will induce tumor cell death. Therefore, cancer cells have evolved mechanisms to protect themselves from intrinsic oxidative stress and have developed a sophisticated adaptation system that essentially involves the rearrangement of the antioxidant functions and the upregulation of pro-survival molecules (16, 17) . In addition to the increase in mutations rate, ROS could contribute to the initiation of cancer through accelerating pro-tumorigenic signaling pathways. By oxidizing disulfide bonds of cysteine residues, ROS could change the activity of certain proteins, and particularly the tyrosine phosphatases superfamily (18) . Perhaps the best example related to cancer is the documented inactivation of the tumor suppressor PTEN by oxidation (19, 20) . Another example is the inhibition of the MAP kinase phosphatase by ROS, which in turn induces activation of ERKs.
The inhibition of PTEN by ROS hyperactivates the PI3K/Akt signaling pathway, which is perhaps the most frequently activated signaling pathway in cancer cells [reviewed in (21−23) ].
The activation of this pathway would further increase intracellular ROS, at least in part, through
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ROS as a double-edged sword in cancer cells
The high intracellular ROS levels in cancer cells are largely the by-products of the highly metabolic nature of these cells. These ROS levels could be pro-tumorigenic, but also increase the susceptibility of cancer cells to cell death. Activated signaling pathways that increase intracellular ROS level in cancer cells render these cells more vulnerable than normal cells to oxidative stress-induced cell death. This vulnerability was documented in cells expressing oncogenic Ras (25) and in cells that display hyperactive PI3K/Akt signaling (24) . The high levels of ROS in cancer cells that display hyperactive Akt is generated by increased mitochondrial metabolism and by the suppression of anti-oxidants gene expression, through the inhibition of FOXO transcription factor (24) . In addition to the elevation of SOD2 and catalase, FOXO was shown to induce the expression of Sestrin3 (24, 26) . Sestrin3 is a member of a family of proteins that includes Sestrin1 and Sestrin2, which were originally identified as antioxidants induced by the tumor suppressor p53 (27−30) . The FOXO-Sestrin axis is conserved in flies, and has an additional function in both mammalian and flies cells as an activator of AMPK and the inhibitor of mTORC1 (26, 31) . Thus, the suppression of Sestrins expression in cancer cells could increase intracellular ROS and activate mTORC1. Because ROS inhibits PTEN activity, this would further activate the PI3K/Akt signaling in Pten-proficient cells and further activate mTORC1 ( Fig. 2A ). To maintain the intracellular level of ROS below a toxic threshold level, cancer cells adopted alternative mechanisms of anti-oxidation. For instance, relatively high levels of FOXM1 expression in cancer cells could compensate for the loss of FOXO activity.
FOXM1 is expressed at low levels in normal cells, but its expression is markedly elevated in cancer cells (32) . FOXM1 exerts multiple pro-tumorigenic activities, but was also shown to reduce ROS levels through the transcriptional induction of SOD2, catalase, and mitochondrial thioredoxin-dependent peroxide reductase (PRDX3) (33) . In addition, the expression of detoxifying enzymes such as glutathione S-transferases (GSTs), NAD(P)H:quinone oxidoreductase 1 (NQO1) was reported to be elevated in cancer cells (34, 35) . from the matrix and translocate to the lumen (36), or during metastasis when they leave the primary tumor site to relocate to another site. The decrease in glucose uptake during these processes suppresses ATP production and activates AMPK (36, 37) , but also inhibits the generation of NADPH via the PPP. The reduced level of NADPH results in increase of intracellular ROS, which could eventually cause cell death (36, 37) . However, the concomitant activation of AMPK elicits alternative mechanisms that maintain intracellular NADPH levels.
The activated AMPK phosphorylates and inhibits acetyl-CoA carboxylase 1 (ACC1) and ACC2.
Both enzymes may have some overlapping activities, but ACC1 is largely responsible for the generation of malonyl-CoA for fatty acid synthesis (FAS), whereas ACC2 inhibits fatty acid oxidation (FAO) (38) . By inhibiting ACC1, AMPK inhibits FAS and therefore decreases NADPH consumption in FAS. By inhibiting ACC2, AMPK increases FAO and therefore NADPH production via the mitochondria (37) (Fig. 2B) . Thus, AMPK activation is critical for the adaptation of cancer cells to energetic stress, which subsequently induces oxidative stress.
CLINICAL-TRANSLATIONAL ADVANCES
The high levels of ROS in cancer cells in comparison to normal cells could be exploited for cancer therapy. In fact, many of the commonly used chemotherapeutic regimens induce high level of ROS that kill cancer cells (39, 40) . However most of these therapeutic regimens were not strictly developed to exploit the high level of ROS in cancer cells for cancer therapy.
The persistent pro-oxidative state characterizing cancer cells, as well as their multiple adaptation mechanisms, can be exploited to develop new therapeutic strategies that will specifically target cancer cells, in order to ensure a good therapeutic selectivity. Because the overall redox homeostasis is maintained by the balance between ROS generation and scavenging, exogenous compounds that specifically increase ROS production, or inhibit ROS elimination, can favor the accumulation of ROS in cancer cells, and hence induce cell damage or even cell death once their threshold of "tolerance" is reached (41) .
ROS and Chemotherapy
Developing cancer therapies based on escalating further the high ROS level in cancer cells to a toxic level by triggering ROS accumulation directly and/or inhibition of ROS scavenging
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systems represent powerful avenues for selectively killing cancer cells. Several drugs have been identified as promoting ROS generation. These reagents include: (i) mitochondrial electron transport chain modulators (e.g., arsenic trioxide, doxorubicin, topotecan); (ii) redox-cycling compounds (e.g., motexafin gadolinium); (iii) agents that disrupt the antioxidant defenses mechanism, such as GSH depleting agents (e.g., buthionine sulphoximine, β-phenylethyl isothiocyanates (PEITC)) and inhibitors of SOD (e.g., 2-methoxyestradiol), and catalase (e.g., 3-amino-1,2,4-triazole) (25, 41−44) . Through promoting oxidative stress or targeting the endogenous antioxidant system of cancer cells, these reagents could be used as a therapeutic weapon against cancer cells.
Rapamycin and oxidative stress combination as cancer therapy
The PI3K/AKT signaling pathway is thought to play a prominent role in the initiation and maintenance of human cancer, as many components of this pathway have been found to be mutated or amplified in a broad range of human cancers (21−23) and thereby promoting resistance to therapeutic agents that induce apoptosis.
Akt is activated by extracellular signals that activate phosphatidylinositol 3-kinase (PI3K), and is negatively regulated by phospholipid phosphatases that negate the activity of PI3K, such as the tumor suppressor PTEN. Akt activity is also downregulated by the activation of its downstream effector, the mammalian target of rapamycin complex 1 (mTORC1), which in turn induces a negative feedback mechanism that inhibits Akt activity (21, 22, 45) . By virtue of its role in energy metabolism Akt can regulate the mitochondrial production of byproducts of energy metabolism, ROS. Akt can also regulate ROS, via its negative effects on FoxO transcription factor leading to downregulation of SOD2, catalase, and Sestrin3 (24) (Fig. 2A) .
Thus, the high levels of ROS as a consequence of Akt activation is due to an enhancement of mitochondrial activity as well as the downregulation of antioxidant defense mechanisms. In other words, Akt sensitizes cells to oxidative-stress induced apoptosis, by lowering the threshold of oxidative stress needed to induce cell death, and this could be exploited to selectively eradicate and to overcome chemoresistance of cancer cells with hyperactivated Akt.
Rapamycin analogs are currently being used in clinical trials and have been already approved for certain types of cancer (46, 47) . Rapamycin alone attenuates cell proliferation and rarely elicits cell death. Furthermore, it could also increase cell survival and chemoresistance via the inhibition of mTORC1, and consequently activating Akt through the inhibition of a negative feedback loop (21, 22, 45) . However, by activating Akt, rapamycin further sensitizes cells to ROS-induced cell death, and thus, the combination of rapamycin and oxidative stress could be an attractive strategy to selectively eradicate cancer cells (24) .
Isothiocyanates such as the PEITC are thiol modifiers that have been shown to inhibit the GSH antioxidant system by extruding GSH from the cell and by inhibiting glutathione peroxidase (25, 44) . This leads to ROS overproduction, oxidative damage of mitochondria, and apoptosis preferentially in cancer cells, presumably due to their increased constitutive ROS levels (24, 25, 44) . Clinical studies with PEITC are currently being initiated (48). A combination therapy of rapamycin and PEITC was proven efficient to selectively eradicate tumors with hyperactivated Akt in pre-clinical studies (24) . This strategy evades the chemoresistance induced by the hyperactivation of Akt in cancer cells.
Agents that enhance proteotoxic stress, including the HSP90 inhibitor IPI-504, are also known ROS inducers. It has been shown that IPI-504 and rapamycin synergize in Ras-driven tumors by promoting irresolvable ER stress, resulting in catastrophic ER and mitochondrial damage, and tumor regression (49) . The mechanism by which these agents cooperate reveals a therapeutic paradigm that can be expanded to develop additional combinations.
FOXM1 inhibition and oxidative stress combination as cancer therapy
The transcription factor FOXM1 is overexpressed in a majority of human tumors and is implicated in tumor angiogenesis, invasion and metastasis (32) . Increased FOXM1 expression in tumors is associated with advanced tumor stage and poor prognosis. FOXM1 could reduce intracellular ROS levels in cancer cells by inducing the expression of detoxifying enzymes, including catalase, SOD2, and PRDX3 (33) (Fig. 2A) . 
Targeting AMPK for cancer therapy
AMPK is a master switch of metabolic adaptation (37, 54, 55) , and its activation appears to be critical for cell survival during energetic stress (37) (Fig. 2B) . The activation of AMPK could inhibit the proliferation of cancer cells and therefore is a considered strategy for cancer therapy (55) . However, the recent studies discussed above, which show that AMPK activation is required to combat oxidative stress and promote cancer cell survival during energetic stress, suggest that the inhibition of AMPK could be also a therapeutic strategy for cancer therapy. This could be an effective therapy at certain stages of cancer progression such as during solid tumor formation and metastasis when cancer cells undergo energetic stress. Since the absence of AMPK activation during energetic stress of cancer cells elicits ROS-mediated cell death, the combination of exogenous ROS inducers and inhibitors of AMPK could be another attractive strategy for cancer therapy.
Sestrin proteins activate AMPK and also reduce ROS. As shown recently, under energetic stress conditions, Sestrin 2 expression is elevated and further potentiates AMPK activity (56, 57) . Therefore, targeting Sestrins could not only elevate intracellular ROS but also attenuate AMPK activation during energetic stress, and may constitute another strategy for cancer therapy.
The use of AMPK activation for cancer therapy may stop cancer cell proliferation, but may also increase survival of cancer cells during solid tumor formation and metastasis. To circumvent this possibility and render AMPK activation a more potent therapeutic approach it would be useful to employ AMPK activation in combination with pharmacological activators of ACCs to counteract the pro-survival activity of AMPK activation (37) . In summary, we described elevated ROS level as one hallmark of cancer cells that could be exploited for selective cancer therapy. ROS are pro-tumorigenic but also toxic above a certain threshold level. This threshold level could be easily achieved in cancer cells by a relatively subtle increase in ROS level that does not increase ROS level to a toxic level in normal cells. We described several potential therapeutic strategies using ROS inducers alone or in combination with other therapeutic regimens. However, the same as with many therapeutic regimens, ROS inducers could be pro-tumorigenic for normal cells. Therefore, ROS inducers should be kept at restricted doses in order not to affect normal cells. 
